Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jingmei Zuckett is active.

Publication


Featured researches published by Jingmei Zuckett.


Bioorganic & Medicinal Chemistry Letters | 2003

Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors

Wenrong Huang; Penglie Zhang; Jingmei Zuckett; Lingyan Wang; John Woolfrey; Yonghong Song; Zhaozhong J. Jia; Lane Clizbe; Ting Su; Katherine Tran; Brian Huang; Paul Wong; Uma Sinha; Gary Park; Andrea Reed; John Malinowski; Stanley J. Hollenbach; Robert M. Scarborough; Bing-Yan Zhu

A series of benzoxazinone derivatives was designed and synthesized as factor Xa inhibitors. We demonstrated that the naphthyl moiety in the aniline-based compounds 1 and 2 can be replaced with benzene-fused heterobicycles and biaryls to give factor Xa inhibitors with improved trypsin selectivity. The P4 modifications lead to monoamidines which are moderately active. The benzoxazinones 41-45 are potent against factor Xa, retain the improved trypsin selectivity of the corresponding aniline-based compounds, and show strong antithrombotic effect dose responsively.


Bioorganic & Medicinal Chemistry Letters | 2002

Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors

Penglie Zhang; Jingmei Zuckett; John Woolfrey; Katherine Tran; Brian Huang; Paul Wong; Uma Sinha; Gary Park; Andrea Reed; John Malinowski; Stan Hollenbach; Robert M. Scarborough; Bing-Yan Zhu

Monoamidine FXa inhibitors 3 were designed and synthesized. SAR studies and molecular modeling led to the design of conformationally constrained diaryl ethers 4 and 5, as well as benzopyrrolidinone 7 as potent FXa inhibitors. The monoamidines show high efficacy in a DVT model, but lack desirable oral bioavailability. The benzopyrrolidinone-based aminoisoquinolines 8 do not show significant improvement in oral bioavailability.


Archive | 2001

Benzamides and related inhibitors of factor Xa

Bing-Yan Zhu; Penglie Zhang; Lingyan Wang; Wenrong Huang; Erick A. Goldman; Wenhao Li; Jingmei Zuckett; Yonghong Song; Robert M. Scarborough


Bioorganic & Medicinal Chemistry Letters | 2004

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs

Penglie Zhang; Liang Bao; Jingmei Zuckett; Erick A. Goldman; Zhaozhong J. Jia; Ann E. Arfsten; Susan T. Edwards; Uma Sinha; Athiwat Hutchaleelaha; Gary Park; Joseph L. Lambing; Stanley J. Hollenbach; Robert M. Scarborough; Bing-Yan Zhu


Bioorganic & Medicinal Chemistry Letters | 2004

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.

Penglie Zhang; Liang Bao; Jingmei Zuckett; Zhaozhong J. Jia; John Woolfrey; Ann E. Arfsten; Susan T. Edwards; Uma Sinha; Athiwat Hutchaleelaha; Joseph L. Lambing; Stanley J. Hollenbach; Robert M. Scarborough; Bing-Yan Zhu


Archive | 2001

Quaternary amines and related inhibitors of factor xa

Penglie Zhang; Jingmei Zuckett; Liang Bao; Robert M. Scarborough; Bing-Yan Zhu


Bioorganic & Medicinal Chemistry Letters | 2004

N, N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors

Zhaozhong J. Jia; Ting Su; Jingmei Zuckett; Yanhong Wu; Erick A. Goldman; Wenhao Li; Penglie Zhang; Lane Clizbe; Yonghong Song; Shawn M. Bauer; Wenrong Huang; John Woolfrey; Uma Sinha; Ann E. Arfsten; Athiwat Hutchaleelaha; Stanley J. Hollenbach; Joseph L. Lambing; Robert M. Scarborough; Bing-Yan Zhu


Archive | 2000

β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa

Bing-Yan Zhu; Lingyan Wang; Wenrong Huang; Yanhong Wu; Jingmei Zuckett; Ting Su; Robert M. Scarborough


Bioorganic & Medicinal Chemistry Letters | 2004

Parallel synthesis and structure–activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors

Shawn M. Bauer; Erick A. Goldman; Wenrong Huang; Ting Su; Lingyan Wang; John Woolfrey; Yanhong Wu; Jingmei Zuckett; Ann E. Arfsten; Brian Huang; Jaya Kothule; Joyce Lin; Bridget May; Uma Sinha; Paul Wong; Athiwat Hutchaleelaha; Robert M. Scarborough; Bing-Yan Zhu


Archive | 2001

Benzamides et inhibiteurs associes du facteur xa

Bing-Yan Zhu; Penglie Zhang; Lingyan Wang; Wenrong Huang; Erick A. Goldman; Wenhao Li; Jingmei Zuckett; Yonghong Song; Robert M. Scarborough

Collaboration


Dive into the Jingmei Zuckett's collaboration.

Top Co-Authors

Avatar

Bing-Yan Zhu

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Penglie Zhang

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Wenrong Huang

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Lingyan Wang

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Erick A. Goldman

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Yonghong Song

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Uma Sinha

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Wenhao Li

Millennium Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

John Woolfrey

Millennium Pharmaceuticals

View shared research outputs
Researchain Logo
Decentralizing Knowledge